Wegovy vs Ozempic: Same Drug, Different Price—Here's What to Know

Last Updated: January 2026

Wegovy and Ozempic are the same molecule—semaglutide—manufactured by the same company, Novo Nordisk. The only meaningful difference is the maximum dose: Wegovy goes up to 2.4 mg weekly for weight loss, while Ozempic tops out at 2.0 mg weekly for type 2 diabetes. That 0.4 mg gap has created a $14,000 annual price difference for functionally identical treatment. As of January 2026, Novo Nordisk announced it would cut Wegovy's list price by 50% and Ozempic's by 35%, bringing the new list prices to approximately $675 and $529 per month respectively. Even with these reductions, the pricing disparity remains significant—and the reasons why expose fundamental problems in how America prices prescription drugs.

The FDA approved semaglutide first as Ozempic for type 2 diabetes in 2017, then as Wegovy for chronic weight management in 2021. Both are glucagon-like peptide-1 (GLP-1) receptor agonists that slow gastric emptying, reduce appetite, and improve insulin sensitivity. In clinical trials, patients taking Wegovy 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo, according to the STEP 1 trial published in The New England Journal of Medicine in 2021. Ozempic at 1.0 mg showed similar weight loss—roughly 12-14% in real-world studies—despite being marketed for diabetes.

Here's where it gets expensive. Before the 2026 price cuts, Wegovy's list price was approximately $1,349 per month. Ozempic was around $969 per month. That means patients paid a 39% premium for Wegovy, despite getting the same active ingredient at a dose that's only 20% higher. The new pricing still maintains a 28% premium for Wegovy over Ozempic. Insurance companies have exploited this gap by covering Ozempic for diabetes but denying Wegovy for obesity, even though obesity is a recognized chronic disease affecting 42.4% of US adults, per CDC 2024 data.

The Dosing Game

Semaglutide follows the same dose escalation schedule regardless of brand name. Patients typically start at 0.25 mg weekly for four weeks, increase to 0.5 mg for four weeks, then 1.0 mg, then 1.7 mg, and finally 2.4 mg. The escalation prevents gastrointestinal side effects—nausea, vomiting, diarrhea—that occur when GLP-1 receptors are activated too quickly. Ozempic pens contain doses up to 2.0 mg. Wegovy pens go to 2.4 mg.

The FDA's own approval documents show no clinically significant difference in weight loss between 2.0 mg and 2.4 mg doses. A 2022 post-hoc analysis from the STEP trials found that patients at 2.0 mg lost an average of 14.2% of body weight compared to 14.9% at 2.4 mg—a difference of 0.7 percentage points, well within statistical noise. Dr. Robert Kushner, lead investigator on multiple semaglutide trials, stated in the 2021 STEP 1 publication: "The majority of weight loss occurred by week 60, with patients maintaining weight loss through week 68 on the 2.4-mg dose."

Parameter	Ozempic (2.0 mg)	Wegovy (2.4 mg)
Active Ingredient	Semaglutide	Semaglutide
Maximum Weekly Dose	2.0 mg	2.4 mg
Average Weight Loss (68 weeks)	~14.2%	~14.9%
List Price (2026, per month)	~$529	~$675
Annual Cost Difference	—	+$1,752

Some endocrinologists prescribe Ozempic off-label for weight loss at the 2.0 mg maintenance dose. This is legal and common. Off-label prescribing accounts for approximately 20% of all US prescriptions across all drug categories, according to a 2016 study in JAMA Internal Medicine. Insurers cover off-label Ozempic for weight loss inconsistently. Some require documented diabetes or prediabetes. Others deny coverage entirely, forcing patients into cash pay or telehealth arbitrage.

The Telehealth Workaround

Cash-pay telehealth platforms have exploited the Ozempic-Wegovy price gap aggressively. GoodRx offers prefilled pens of semaglutide 0.25 mg and 0.50 mg for $199 for the first two fills, plus a $39 monthly fee for unlimited online care. After the introductory period, patients pay $349 per month in cash. Hims & Hers, Calibrate, and Ro offer similar programs, typically charging $297 to $495 monthly including medication and virtual provider visits.

These platforms prescribe compounded semaglutide when brand-name drugs are unavailable or unaffordable. Compounded semaglutide is not FDA-approved but is legal under the Federal Food, Drug, and Cosmetic Act when a drug is on the FDA's shortage list. Semaglutide appeared on the shortage list in March 2022 and remained there through most of 2024, allowing compounding pharmacies to produce generic versions at a fraction of brand-name cost. Novo Nordisk has challenged this practice, arguing that compounded versions lack safety data and proper quality controls.

The FDA updated its guidance in December 2024, stating that compounded drugs must be made in facilities registered under section 503B of the FD&C Act and that "compounded semaglutide products have been associated with adverse events including dosing errors and contamination." As of January 2026, semaglutide is off the shortage list, meaning compounding pharmacies can no longer legally produce it except for individual patient prescriptions meeting specific criteria. This has forced many telehealth platforms to pivot to brand-name prescriptions or alternative GLP-1 drugs like tirzepatide.

What Providers Can Actually Prescribe

Any licensed prescriber—physician, nurse practitioner, physician assistant—can prescribe both Ozempic and Wegovy. No special certification exists. No prior authorization is required from the FDA. The barrier is insurance coverage, not prescribing authority. Endocrinologists, primary care doctors, obesity medicine specialists, and telehealth providers all prescribe semaglutide at similar rates.

Insurance companies impose their own restrictions through formularies and step therapy protocols. A typical commercial insurance plan requires patients to try phentermine or another older weight-loss drug before approving Wegovy. Some plans require a BMI above 30 kg/m² (obese) or above 27 kg/m² with at least one weight-related comorbidity like hypertension or sleep apnea. Medicare explicitly does not cover weight-loss medications under Part D unless they're approved for another condition, per the Social Security Act's Section 1862 exclusion. This means Medicare beneficiaries can get Ozempic covered for diabetes but not Wegovy for obesity, even if obesity causes their diabetes.

Medicaid coverage varies by state. As of 2025, only 13 states cover GLP-1 drugs for weight loss under their Medicaid programs, according to the Kaiser Family Foundation. The remaining 37 states deny coverage, citing budget constraints. This creates a bizarre scenario where low-income patients with the highest obesity rates—42.9% among adults earning less than $25,000 annually per CDC data—have the least access to effective treatment.

The Price Cut Reality

Novo Nordisk's January 2026 price reduction sounds generous: 50% off Wegovy, 35% off Ozempic. The new list prices of approximately $675 and $529 monthly are still multiples of what European countries pay. In Germany, Wegovy costs roughly €300 ($320) per month. In the UK, the NHS negotiated a price of approximately £200 ($250) per month. Denmark, where Novo Nordisk is headquartered, pays around 1,800 DKK ($260) per month.

The US pays 2.6 times what Europe pays for the same drug from the same manufacturer. This gap exists because the US lacks centralized price negotiation. The Inflation Reduction Act of 2022 allows Medicare to negotiate prices for a limited number of drugs starting in 2026, but semaglutide is not on the initial list. Private insurers negotiate separately, with widely varying results. A 2024 analysis by the Institute for Clinical and Economic Review (ICER) found that health plans pay between $800 and $1,200 per month for Wegovy after rebates—still far above European prices.

The price cuts also don't address the fundamental problem: patients without insurance or with high-deductible plans still face sticker shock. A patient with a $5,000 annual deductible will pay $4,050 out of pocket for six months of Wegovy under the new pricing before insurance kicks in. Novo Nordisk offers a savings card capping costs at $25 per month, but it excludes patients on government insurance and has income limits that disqualify many middle-class families.

Why This Matters

The Ozempic-Wegovy price gap is a case study in pharmaceutical market dysfunction. Novo Nordisk charges different prices for the same molecule based on indication, not cost of production or clinical benefit. The dose difference is trivial. The manufacturing process is identical. The packaging differs only in labeling. Yet the company extracts billions in additional revenue by segmenting the market.

This isn't unique to semaglutide. Insulin manufacturers have used similar tactics for decades, pricing the same insulin analog differently based on whether it's sold as a vial, pen, or pump cartridge. The FDA has no authority to regulate drug prices, only safety and efficacy. Congress has repeatedly failed to pass meaningful price reform. The result is a system where Americans pay more for drugs than any other developed country while outcomes remain middling.

Obesity costs the US healthcare system an estimated $173 billion annually in direct medical costs, according to a 2019 study in Obesity. Effective pharmacotherapy could reduce those costs substantially, but only if people can access it. Right now, access depends on insurance status, employer generosity, geographic location, and willingness to navigate bureaucratic obstacles. A 2023 survey by the Obesity Action Coalition found that 68% of patients prescribed Wegovy never filled their first prescription due to cost.

The same drug under two names at two prices is not a free market—it's market segmentation enabled by regulatory gaps and insurance complexity. Patients prescribed Ozempic off-label get functionally identical treatment at a 28% discount post-price cut. Those following FDA labeling pay a premium for a marginal dose increase. The difference isn't clinical. It's financial engineering.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002.
2. Centers for Disease Control and Prevention. Adult Obesity Facts. Updated 2024.